This study reveals a novel mechanism of endothelial-astrocyte crosstalk in NMOSD, suggesting that targeting the VEGFA signaling pathway can enhance astrocytic complement defense, offering new experimental design strategies for disease intervention.
Literature Overview
The article titled 'Endothelial cell-secreted SPARC suppresses astrocytic CD59 expression and promotes astrocytopathy in a mouse model of neuromyelitis optica spectrum disorders,' published in Nature Communications, systematically investigates how the brain microenvironment regulates astrocyte susceptibility to complement-mediated injury in a mouse model of neuromyelitis optica spectrum disorders (NMOSD). The study focuses on the regulatory mechanisms of CD59, a complement inhibitor on astrocytes, and reveals that brain microvascular endothelial cells secrete the SPARC protein to inhibit the VEGFA/VEGFR2 signaling pathway, thereby downregulating CD59 expression and rendering astrocytes vulnerable to AQP4-IgG and complement attack. This finding fills a critical gap in understanding complement regulation in central nervous system autoimmune diseases.Background Knowledge
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system primarily affecting the optic nerves and spinal cord. Its core pathological feature is astrocytopathy, driven by complement-dependent cytotoxicity (CDC) initiated by autoantibodies against aquaporin-4 (AQP4-IgG). Although CD59, a membrane-bound complement regulatory protein (mCRP), effectively inhibits formation of the membrane attack complex (MAC) and protects cells from complement-mediated lysis, its expression in the central nervous system is significantly lower than in peripheral tissues, suggesting the presence of unique regulatory mechanisms. Current understanding of how CD59 expression is downregulated in NMOSD remains limited, particularly regarding systemic analysis of intercellular interactions within the brain microenvironment. Traditional studies have largely focused on intrinsic astrocyte regulation, overlooking paracrine influences from neighboring cells such as endothelial cells. This study investigates whether crosstalk between endothelial cells and astrocytes at the blood-brain barrier regulates CD59 expression and thereby influences disease progression.
Research Methods and Experiments
The authors first established a clinically relevant mouse model of NMOSD by stereotaxically injecting AQP4-IgG and human complement into the striatum of female mice, successfully recapitulating the pathological hallmark of astrocyte loss. Single-cell RNA sequencing (scRNA-seq) revealed significantly downregulated CD59 expression in astrocytes in the NMOSD-like mice. To validate its functional role, the authors used AAV vectors to specifically overexpress CD59 in astrocytes, which significantly reduced the loss of AQP4 and GFAP in lesioned areas, demonstrating a protective function of CD59.
To further explore the regulatory mechanism, co-culture and conditioned medium (bCM) experiments were conducted, revealing that factors secreted by brain microvascular endothelial cells (bEnd.3) suppressed CD59 expression in primary astrocytes. Integrated secretome and transcriptome analyses identified SPARC, highly expressed in endothelial cells, as the key inhibitory factor. ELISA and functional assays showed that knockdown of SPARC in endothelial cells reversed their suppressive effect on astrocytic CD59, while exogenous recombinant SPARC dose-dependently reduced CD59 levels.
In animal models, endothelial-specific SPARC knockout mice (Sparc-cKO) exhibited increased CD59 expression in astrocytes and significantly attenuated NMOSD-like pathology. Mechanistically, RNA-seq and Western blot analyses demonstrated that SPARC inhibits the VEGFR2 and downstream MAPK signaling pathways, thereby negatively regulating CD59 expression. Functional experiments further confirmed that administration of a VEGFR2 inhibitor (SU5416) exacerbated lesions, whereas treatment with VEGFA promoted astrocyte proliferation, upregulated CD59, and alleviated disease phenotypes. Molecular docking and MetaSPR assays confirmed direct binding between SPARC and VEGFA, antagonizing its pro-survival signaling.Key Conclusions and Perspectives
Research Significance and Prospects
This study mechanistically uncovers a novel cause of astrocyte vulnerability in NMOSD—endothelial-derived SPARC-mediated suppression of CD59. It provides a new perspective on the role of the blood-brain barrier in neuroinflammation, suggesting that future therapies should not only target the immune system but also aim to protect intrinsic glial defense mechanisms.
From a drug development standpoint, this study supports targeting SPARC or enhancing VEGFA signaling as potential therapeutic strategies, enabling the design of small-molecule inhibitors, neutralizing antibodies, or gene therapies. Furthermore, CD59 expression levels could serve as a biomarker for predicting disease activity or treatment response, advancing personalized medicine.
In terms of disease modeling, the study emphasizes the importance of preserving brain microenvironment integrity when constructing NMOSD models, recommending the use of more sophisticated co-culture systems or humanized models to better recapitulate pathological processes. Future studies could employ conditional knockout mouse models to further validate SPARC functions in distinct cell types, enhancing mechanistic precision.
Conclusion
This study systematically reveals that endothelial cell-secreted SPARC suppresses astrocytic CD59 expression by antagonizing the VEGFA/VEGFR2 signaling pathway, thereby promoting complement-mediated astrocyte injury in NMOSD. This finding not only deepens our understanding of NMOSD pathogenesis but also introduces a new therapeutic paradigm of 'protecting astrocytes.' From bench to bedside, this research provides a solid foundation for developing therapies targeting endothelial-astrocyte crosstalk, such as delivering VEGFA or blocking SPARC to enhance endogenous complement defense. Moreover, CD59 levels may serve as a monitoring biomarker for disease activity, supporting precision medicine. This work offers a complete pathway from mechanistic insight to intervention strategies for NMOSD care, paving the way for next-generation treatments in neuroimmune disorders.
